Britannia Life Sciences (L020) 주식 개요는 주로 영국 및 전 세계의 화장품, 소비재 및 생활용품, 건강기능식품 업계에 제품 테스트, 안전성 평가, 규정 준수 서비스를 제공하는 기업입니다. 자세히 보기L020 펀더멘털 분석스노우플레이크 점수가치 평가2/6미래 성장0/6과거 실적3/6재무 건전성4/6배당0/6강점주가수익률(1.3x)이 German 시장(17.4x)보다 낮습니다.올해부터 흑자전환위험 분석지난 3개월 동안 주가 변동성이 German 시장과 비교했을 때 매우 높았습니다.높은 수준의 비현금 수입수익이 USD$1m 미만입니다(CA$158K)의미 있는 시가총액이 없습니다(€7M)모든 위험 점검 보기L020 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW472,506 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA472,506 investors already sharing narrativesYour Fair Value€Current Price€0.025880.8% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-10m8m2016201920222025202620282031Revenue CA$13.2kEarnings CA$665.4kAdvancedSet Fair ValueView all narrativesBritannia Life Sciences Inc. 경쟁사AquamondiSymbol: DUSE:APQMarket cap: €4.4mJostSymbol: MUN:JOXMarket cap: €2.8m11880 SolutionsSymbol: XTRA:TGTMarket cap: €12.7mDGA Spólka AkcyjnaSymbol: WSE:DGAMarket cap: zł23.3m가격 이력 및 성과Britannia Life Sciences 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CA$0.02552주 최고가CA$0.07152주 최저가CA$0.025베타-0.0701개월 변동-20.31%3개월 변동-38.55%1년 변동-43.33%3년 변동-52.34%5년 변동n/aIPO 이후 변동-81.11%최근 뉴스 및 업데이트Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. CEO & Director Pete Shippen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Jan 14Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026.공고 • Nov 03McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB).McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB) on November 3, 2025. McEwen will acquire a 31% equity interest in Britannia Mining Solutions through a strategic investment by purchasing 648,002 shares from Britannia Life Sciences Inc. and 226,286 shares from Paragon Geochemical Laboratories Inc. via a private placement, both at a deemed price of CAD 17.50 per Britannia Mining Solutions share. The total consideration of CAD 15.3 million will be payable in shares of McEwen. Upon completion of the transaction, McEwen will become Britannia Mining Solutions largest shareholder. Ian Ball, Vice-Chairman of McEwen, will join Britannia Mining Solutions board at the time of listing. In addition, McEwen will have the right to nominate one additional board member.공고 • Jul 28Britannia Life Sciences Inc. announced that it expects to receive CAD 10 million in fundingBritannia Life Sciences Inc. announced a non-brokered private placement offering of unsecured debentures for gross proceeds of up to CAD 10 million on July 28, 2025. To bear interest at 18% per annum, paid monthly subject to a 60 day delayed accrual, to have a 10-year term from the date of issuance, to be listed on the CSE (subject to prior satisfaction of all CSE listing requirements with respect to the Debentures), to be redeemable by the Company after 2 years at 101% of the then-prevailing market price, to be offered in minimum subscriptions of $50,000. The offering is expected to close on or before September 15, 2025.공고 • Jan 10+ 1 more updateBritannia Life Sciences Inc. (CNSX:BLAB) agreed to acquire remaining 28% stake in Advanced Development & Safety Laboratories Limited for approximately £8.1 million.Britannia Life Sciences Inc. (CNSX:BLAB) agreed to acquire remaining 28% stake in Advanced Development & Safety Laboratories Limited for approximately £8.1 million on January 9, 2025. The amount paid by Britannia pursuant to the Consolidating Acquisition includes £6.1 million for the acquisition of the minority shares and £2 million in intercompany loan settlements, subject to final adjustments, and will be funded from the proceeds of the Transaction. Upon completion, Britannia Life Sciences Inc. will own 100% stake in Advanced Development & Safety Laboratories Limited. Canaccord Genuity Limited acted as financial advisor for Britannia Life Sciences Inc. Bennett Jones Services Limited Partnership acted as legal advisor for Britannia Life Sciences Inc. Gowling WLG LLP acted as legal advisor for Britannia Life Sciences Inc.Buy Or Sell Opportunity • Oct 23Now 55% undervaluedOver the last 90 days, the stock has risen 19% to €0.022. The fair value is estimated to be €0.049, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.더 많은 업데이트 보기Recent updatesBoard Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. CEO & Director Pete Shippen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.공고 • Jan 14Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026.공고 • Nov 03McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB).McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB) on November 3, 2025. McEwen will acquire a 31% equity interest in Britannia Mining Solutions through a strategic investment by purchasing 648,002 shares from Britannia Life Sciences Inc. and 226,286 shares from Paragon Geochemical Laboratories Inc. via a private placement, both at a deemed price of CAD 17.50 per Britannia Mining Solutions share. The total consideration of CAD 15.3 million will be payable in shares of McEwen. Upon completion of the transaction, McEwen will become Britannia Mining Solutions largest shareholder. Ian Ball, Vice-Chairman of McEwen, will join Britannia Mining Solutions board at the time of listing. In addition, McEwen will have the right to nominate one additional board member.공고 • Jul 28Britannia Life Sciences Inc. announced that it expects to receive CAD 10 million in fundingBritannia Life Sciences Inc. announced a non-brokered private placement offering of unsecured debentures for gross proceeds of up to CAD 10 million on July 28, 2025. To bear interest at 18% per annum, paid monthly subject to a 60 day delayed accrual, to have a 10-year term from the date of issuance, to be listed on the CSE (subject to prior satisfaction of all CSE listing requirements with respect to the Debentures), to be redeemable by the Company after 2 years at 101% of the then-prevailing market price, to be offered in minimum subscriptions of $50,000. The offering is expected to close on or before September 15, 2025.공고 • Jan 10+ 1 more updateBritannia Life Sciences Inc. (CNSX:BLAB) agreed to acquire remaining 28% stake in Advanced Development & Safety Laboratories Limited for approximately £8.1 million.Britannia Life Sciences Inc. (CNSX:BLAB) agreed to acquire remaining 28% stake in Advanced Development & Safety Laboratories Limited for approximately £8.1 million on January 9, 2025. The amount paid by Britannia pursuant to the Consolidating Acquisition includes £6.1 million for the acquisition of the minority shares and £2 million in intercompany loan settlements, subject to final adjustments, and will be funded from the proceeds of the Transaction. Upon completion, Britannia Life Sciences Inc. will own 100% stake in Advanced Development & Safety Laboratories Limited. Canaccord Genuity Limited acted as financial advisor for Britannia Life Sciences Inc. Bennett Jones Services Limited Partnership acted as legal advisor for Britannia Life Sciences Inc. Gowling WLG LLP acted as legal advisor for Britannia Life Sciences Inc.Buy Or Sell Opportunity • Oct 23Now 55% undervaluedOver the last 90 days, the stock has risen 19% to €0.022. The fair value is estimated to be €0.049, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.공고 • Oct 11Britannia Life Sciences Inc. announced that it expects to receive CAD 0.00255 million in fundingBritannia Life Sciences Inc. announced a private placement to issue 2% Unsecured Convertible Debenture at principal amount of CAD 2,550 for gross proceeds of CAD 2,550 on October 10, 2024. Under the terms of the first offering, the company will issue CAD 1,275 principal amount 2% unsecured debentures that will have a two-year term and be convertible into common shares of BMS . Pursuant to the second offering, BMS will directly issue CAD 1,275 principal amount 2% unsecured convertible debentures due two years from closing to investors. Each debenture will automatically convert into 100 common shares of BMS, representing a conversion price of CAD 12.75 per common share.Buy Or Sell Opportunity • Oct 07Now 44% undervalued after recent price dropOver the last 90 days, the stock has fallen 14% to €0.025. The fair value is estimated to be €0.046, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.Buy Or Sell Opportunity • Sep 19Now 47% undervalued after recent price dropOver the last 90 days, the stock has fallen 48% to €0.012. The fair value is estimated to be €0.022, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.Board Change • Sep 17High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Chairman Greg Taylor is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.공고 • Sep 17Britannia Life Sciences Inc., Annual General Meeting, Nov 12, 2024Britannia Life Sciences Inc., Annual General Meeting, Nov 12, 2024.Reported Earnings • Aug 30Full year 2024 earnings released: CA$0.029 loss per share (vs CA$0.031 profit in FY 2023)Full year 2024 results: CA$0.029 loss per share (down from CA$0.031 profit in FY 2023). Revenue: CA$7.57m (up 18% from FY 2023). Net loss: CA$4.77m (down 194% from profit in FY 2023).공고 • Jul 23Britannia Life Sciences Inc. announced that it has received CAD 0.932 million in fundingOn July 22, 2024, Britannia Life Sciences Inc. closed the transaction. The company issued 10% 932 unsecured non convertible subordinated debenture units at an issue price of CAD 1,000 per unit for the gross proceeds of CAD 932,000. The transaction included participation from insiders for CAD 260,000. The company paid finder's fees in the amount of CAD 3,500 in connection with the private placement. The debentures will pay interest at a rate of 10% per annum, paid annually in arrears, and have a maturity date of 12 months from the date of issue, subject to extension at the company's option for an additional 12 months.Buy Or Sell Opportunity • Jul 02Now 31% undervalued after recent price dropOver the last 90 days, the stock has fallen 12% to €0.029. The fair value is estimated to be €0.043, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • Jun 27Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 41% to €0.019. The fair value is estimated to be €0.025, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • May 23Now 32% undervalued after recent price dropOver the last 90 days, the stock has fallen 33% to €0.029. The fair value is estimated to be €0.043, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • May 08Now 49% undervalued after recent price dropOver the last 90 days, the stock has fallen 18% to €0.036. The fair value is estimated to be €0.071, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable.Buy Or Sell Opportunity • Mar 14Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.5% to €0.033. The fair value is estimated to be €0.044, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable.Reported Earnings • Mar 01Third quarter 2024 earnings released: EPS: CA$0.003 (vs CA$0 in 3Q 2023)Third quarter 2024 results: EPS: CA$0.003 (up from CA$0 in 3Q 2023). Revenue: CA$1.81m (up 9.6% from 3Q 2023). Net income: CA$535.3k (up CA$589.7k from 3Q 2023). Profit margin: 30% (up from net loss in 3Q 2023).공고 • Dec 01Britannia Life Sciences Inc. (CNSX:BLAB) acquired additional 2% stake in Advanced Development & Safety Laboratories Limited for $0.943 million.Britannia Life Sciences Inc. (CNSX:BLAB) acquired additional 2% stake in Advanced Development & Safety Laboratories Limited for $0.943 million on November 22, 2023. The acquisition increases the Company's ownership interest in ADSL to 72%.Britannia Life Sciences Inc. (CNSX:BLAB) completed the acquisition of additional 2% stake in Advanced Development & Safety Laboratories Limited on November 22, 2023.Reported Earnings • Dec 01Second quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.007 in 2Q 2023)Second quarter 2024 results: EPS: CA$0.004 (down from CA$0.007 in 2Q 2023). Revenue: CA$2.07m (up 30% from 2Q 2023). Net income: CA$724.2k (down 33% from 2Q 2023). Profit margin: 35% (down from 68% in 2Q 2023).Board Change • Sep 08High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Chairman Greg Taylor is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 30First quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.031 profit in 1Q 2023)First quarter 2024 results: CA$0.001 loss per share (down from CA$0.031 profit in 1Q 2023). Revenue: CA$1.95m (up 29% from 1Q 2023). Net loss: CA$117.7k (down 103% from profit in 1Q 2023).New Risk • Aug 01New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.2x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (17% average weekly change). High level of non-cash earnings (33% accrual ratio). Minor Risks Revenue is less than US$5m (CA$6.4m revenue, or US$4.8m). Market cap is less than US$100m (€9.46m market cap, or US$10.4m).Reported Earnings • Aug 01Full year 2023 earnings released: EPS: CA$0.031 (vs CA$0.14 loss in FY 2022)Full year 2023 results: EPS: CA$0.031 (up from CA$0.14 loss in FY 2022). Revenue: CA$6.40m (down 12% from FY 2022). Net income: CA$5.08m (up CA$20.5m from FY 2022). Profit margin: 79% (up from net loss in FY 2022).공고 • Jul 29Britannia Life Sciences Inc., Annual General Meeting, Sep 26, 2023Britannia Life Sciences Inc., Annual General Meeting, Sep 26, 2023.New Risk • Jul 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.94m (US$9.84m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue has declined by 6.8% over the past year. Market cap is less than US$10m (€8.94m market cap, or US$9.84m). Minor Risk Revenue is less than US$5m (CA$6.5m revenue, or US$4.9m).Buying Opportunity • Jul 26Now 29% undervalued after recent price dropOver the last 90 days, the stock is down 3.6%. The fair value is estimated to be €0.057, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 57% over the last 3 years. Earnings per share has declined by 4.3%.Buying Opportunity • Apr 26Now 31% undervaluedOver the last 90 days, the stock is up 47%. The fair value is estimated to be €0.07, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 57% over the last 3 years. Earnings per share has declined by 4.3%.Buying Opportunity • Mar 15Now 22% undervaluedOver the last 90 days, the stock is up 35%. The fair value is estimated to be €0.064, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 57% over the last 3 years. Earnings per share has declined by 4.3%.Reported Earnings • Mar 02Third quarter 2023 earnings released: EPS: CA$0 (vs CA$0.083 loss in 3Q 2022)Third quarter 2023 results: EPS: CA$0 (improved from CA$0.083 loss in 3Q 2022). Revenue: CA$1.65m (flat on 3Q 2022). Net loss: CA$54.3k (loss narrowed 100% from 3Q 2022).Reported Earnings • Nov 30Second quarter 2023 earnings releasedSecond quarter 2023 results: EPS: CA$0.007. Revenue: CA$1.59m (down 17% from 2Q 2022). Net income: CA$1.08m (up CA$1.88m from 2Q 2022). Profit margin: 68% (up from net loss in 2Q 2022).Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Greg Taylor was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Aug 31First quarter 2023 earnings released: EPS: CA$0.031 (vs CA$0.008 in 1Q 2022)First quarter 2023 results: EPS: CA$0.031 (up from CA$0.008 in 1Q 2022). Revenue: CA$1.51m (down 24% from 1Q 2022). Net income: CA$3.42m (up 449% from 1Q 2022).Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Greg Taylor was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Mar 10No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Greg Taylor was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.주주 수익률L020DE Professional ServicesDE 시장7D0%1.3%1.2%1Y-43.3%5.0%0.7%전체 주주 수익률 보기수익률 대 산업: L020은 지난 1년 동안 5%의 수익을 기록한 German Professional Services 산업보다 저조한 성과를 냈습니다.수익률 대 시장: L020은 지난 1년 동안 0.7%를 기록한 German 시장보다 저조한 성과를 냈습니다.주가 변동성Is L020's price volatile compared to industry and market?L020 volatilityL020 Average Weekly Movement12.9%Professional Services Industry Average Movement5.8%Market Average Movement5.4%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.7%안정적인 주가: L020의 주가는 지난 3개월 동안 German 시장보다 변동성이 컸습니다.시간에 따른 변동성: L020의 주간 변동성은 지난 1년간 22%에서 13%로 감소했지만 여전히 German 종목의 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트n/an/aPete Shippenbritannia.life는 주로 영국 및 전 세계의 화장품, 소비재 및 생활용품, 건강기능식품 업계에 제품 테스트, 안전성 평가 및 규정 준수 서비스를 제공하는 회사입니다. 이 회사는 캐나다 토론토에 본사를 두고 있습니다.더 보기Britannia Life Sciences Inc. 기초 지표 요약Britannia Life Sciences의 순이익과 매출은 시가총액과 어떻게 비교됩니까?L020 기초 통계시가총액€6.55m순이익 (TTM)€4.93m매출 (TTM)€97.95k1.3x주가수익비율(P/E)66.9x주가매출비율(P/S)L020는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표L020 손익계산서 (TTM)매출CA$157.68k매출원가CA$344.83k총이익-CA$187.15k기타 비용-CA$8.12m순이익CA$7.93m최근 보고된 실적Dec 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)0.049총이익률-118.69%순이익률5,029.14%부채/자본 비율0.7%L020의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/29 04:50종가2026/07/29 00:00수익2025/12/31연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Britannia Life Sciences Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. CEO & Director Pete Shippen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Jan 14Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026.
공고 • Nov 03McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB).McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB) on November 3, 2025. McEwen will acquire a 31% equity interest in Britannia Mining Solutions through a strategic investment by purchasing 648,002 shares from Britannia Life Sciences Inc. and 226,286 shares from Paragon Geochemical Laboratories Inc. via a private placement, both at a deemed price of CAD 17.50 per Britannia Mining Solutions share. The total consideration of CAD 15.3 million will be payable in shares of McEwen. Upon completion of the transaction, McEwen will become Britannia Mining Solutions largest shareholder. Ian Ball, Vice-Chairman of McEwen, will join Britannia Mining Solutions board at the time of listing. In addition, McEwen will have the right to nominate one additional board member.
공고 • Jul 28Britannia Life Sciences Inc. announced that it expects to receive CAD 10 million in fundingBritannia Life Sciences Inc. announced a non-brokered private placement offering of unsecured debentures for gross proceeds of up to CAD 10 million on July 28, 2025. To bear interest at 18% per annum, paid monthly subject to a 60 day delayed accrual, to have a 10-year term from the date of issuance, to be listed on the CSE (subject to prior satisfaction of all CSE listing requirements with respect to the Debentures), to be redeemable by the Company after 2 years at 101% of the then-prevailing market price, to be offered in minimum subscriptions of $50,000. The offering is expected to close on or before September 15, 2025.
공고 • Jan 10+ 1 more updateBritannia Life Sciences Inc. (CNSX:BLAB) agreed to acquire remaining 28% stake in Advanced Development & Safety Laboratories Limited for approximately £8.1 million.Britannia Life Sciences Inc. (CNSX:BLAB) agreed to acquire remaining 28% stake in Advanced Development & Safety Laboratories Limited for approximately £8.1 million on January 9, 2025. The amount paid by Britannia pursuant to the Consolidating Acquisition includes £6.1 million for the acquisition of the minority shares and £2 million in intercompany loan settlements, subject to final adjustments, and will be funded from the proceeds of the Transaction. Upon completion, Britannia Life Sciences Inc. will own 100% stake in Advanced Development & Safety Laboratories Limited. Canaccord Genuity Limited acted as financial advisor for Britannia Life Sciences Inc. Bennett Jones Services Limited Partnership acted as legal advisor for Britannia Life Sciences Inc. Gowling WLG LLP acted as legal advisor for Britannia Life Sciences Inc.
Buy Or Sell Opportunity • Oct 23Now 55% undervaluedOver the last 90 days, the stock has risen 19% to €0.022. The fair value is estimated to be €0.049, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.
Board Change • May 20Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. No highly experienced directors. CEO & Director Pete Shippen was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
공고 • Jan 14Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026Britannia Life Sciences Inc., Annual General Meeting, Feb 24, 2026.
공고 • Nov 03McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB).McEwen Inc. (NYSE:MUX) signed agreement to acquire an unknown minority stake in Britannia Mining Solutions Inc. from Britannia Life Sciences Inc. (CNSX:BLAB) on November 3, 2025. McEwen will acquire a 31% equity interest in Britannia Mining Solutions through a strategic investment by purchasing 648,002 shares from Britannia Life Sciences Inc. and 226,286 shares from Paragon Geochemical Laboratories Inc. via a private placement, both at a deemed price of CAD 17.50 per Britannia Mining Solutions share. The total consideration of CAD 15.3 million will be payable in shares of McEwen. Upon completion of the transaction, McEwen will become Britannia Mining Solutions largest shareholder. Ian Ball, Vice-Chairman of McEwen, will join Britannia Mining Solutions board at the time of listing. In addition, McEwen will have the right to nominate one additional board member.
공고 • Jul 28Britannia Life Sciences Inc. announced that it expects to receive CAD 10 million in fundingBritannia Life Sciences Inc. announced a non-brokered private placement offering of unsecured debentures for gross proceeds of up to CAD 10 million on July 28, 2025. To bear interest at 18% per annum, paid monthly subject to a 60 day delayed accrual, to have a 10-year term from the date of issuance, to be listed on the CSE (subject to prior satisfaction of all CSE listing requirements with respect to the Debentures), to be redeemable by the Company after 2 years at 101% of the then-prevailing market price, to be offered in minimum subscriptions of $50,000. The offering is expected to close on or before September 15, 2025.
공고 • Jan 10+ 1 more updateBritannia Life Sciences Inc. (CNSX:BLAB) agreed to acquire remaining 28% stake in Advanced Development & Safety Laboratories Limited for approximately £8.1 million.Britannia Life Sciences Inc. (CNSX:BLAB) agreed to acquire remaining 28% stake in Advanced Development & Safety Laboratories Limited for approximately £8.1 million on January 9, 2025. The amount paid by Britannia pursuant to the Consolidating Acquisition includes £6.1 million for the acquisition of the minority shares and £2 million in intercompany loan settlements, subject to final adjustments, and will be funded from the proceeds of the Transaction. Upon completion, Britannia Life Sciences Inc. will own 100% stake in Advanced Development & Safety Laboratories Limited. Canaccord Genuity Limited acted as financial advisor for Britannia Life Sciences Inc. Bennett Jones Services Limited Partnership acted as legal advisor for Britannia Life Sciences Inc. Gowling WLG LLP acted as legal advisor for Britannia Life Sciences Inc.
Buy Or Sell Opportunity • Oct 23Now 55% undervaluedOver the last 90 days, the stock has risen 19% to €0.022. The fair value is estimated to be €0.049, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.
공고 • Oct 11Britannia Life Sciences Inc. announced that it expects to receive CAD 0.00255 million in fundingBritannia Life Sciences Inc. announced a private placement to issue 2% Unsecured Convertible Debenture at principal amount of CAD 2,550 for gross proceeds of CAD 2,550 on October 10, 2024. Under the terms of the first offering, the company will issue CAD 1,275 principal amount 2% unsecured debentures that will have a two-year term and be convertible into common shares of BMS . Pursuant to the second offering, BMS will directly issue CAD 1,275 principal amount 2% unsecured convertible debentures due two years from closing to investors. Each debenture will automatically convert into 100 common shares of BMS, representing a conversion price of CAD 12.75 per common share.
Buy Or Sell Opportunity • Oct 07Now 44% undervalued after recent price dropOver the last 90 days, the stock has fallen 14% to €0.025. The fair value is estimated to be €0.046, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.
Buy Or Sell Opportunity • Sep 19Now 47% undervalued after recent price dropOver the last 90 days, the stock has fallen 48% to €0.012. The fair value is estimated to be €0.022, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 12% over the last 3 years. Meanwhile, the company became loss making.
Board Change • Sep 17High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Chairman Greg Taylor is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
공고 • Sep 17Britannia Life Sciences Inc., Annual General Meeting, Nov 12, 2024Britannia Life Sciences Inc., Annual General Meeting, Nov 12, 2024.
Reported Earnings • Aug 30Full year 2024 earnings released: CA$0.029 loss per share (vs CA$0.031 profit in FY 2023)Full year 2024 results: CA$0.029 loss per share (down from CA$0.031 profit in FY 2023). Revenue: CA$7.57m (up 18% from FY 2023). Net loss: CA$4.77m (down 194% from profit in FY 2023).
공고 • Jul 23Britannia Life Sciences Inc. announced that it has received CAD 0.932 million in fundingOn July 22, 2024, Britannia Life Sciences Inc. closed the transaction. The company issued 10% 932 unsecured non convertible subordinated debenture units at an issue price of CAD 1,000 per unit for the gross proceeds of CAD 932,000. The transaction included participation from insiders for CAD 260,000. The company paid finder's fees in the amount of CAD 3,500 in connection with the private placement. The debentures will pay interest at a rate of 10% per annum, paid annually in arrears, and have a maturity date of 12 months from the date of issue, subject to extension at the company's option for an additional 12 months.
Buy Or Sell Opportunity • Jul 02Now 31% undervalued after recent price dropOver the last 90 days, the stock has fallen 12% to €0.029. The fair value is estimated to be €0.043, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • Jun 27Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 41% to €0.019. The fair value is estimated to be €0.025, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • May 23Now 32% undervalued after recent price dropOver the last 90 days, the stock has fallen 33% to €0.029. The fair value is estimated to be €0.043, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • May 08Now 49% undervalued after recent price dropOver the last 90 days, the stock has fallen 18% to €0.036. The fair value is estimated to be €0.071, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable.
Buy Or Sell Opportunity • Mar 14Now 27% undervalued after recent price dropOver the last 90 days, the stock has fallen 1.5% to €0.033. The fair value is estimated to be €0.044, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 25% over the last 3 years. Meanwhile, the company has become profitable.
Reported Earnings • Mar 01Third quarter 2024 earnings released: EPS: CA$0.003 (vs CA$0 in 3Q 2023)Third quarter 2024 results: EPS: CA$0.003 (up from CA$0 in 3Q 2023). Revenue: CA$1.81m (up 9.6% from 3Q 2023). Net income: CA$535.3k (up CA$589.7k from 3Q 2023). Profit margin: 30% (up from net loss in 3Q 2023).
공고 • Dec 01Britannia Life Sciences Inc. (CNSX:BLAB) acquired additional 2% stake in Advanced Development & Safety Laboratories Limited for $0.943 million.Britannia Life Sciences Inc. (CNSX:BLAB) acquired additional 2% stake in Advanced Development & Safety Laboratories Limited for $0.943 million on November 22, 2023. The acquisition increases the Company's ownership interest in ADSL to 72%.Britannia Life Sciences Inc. (CNSX:BLAB) completed the acquisition of additional 2% stake in Advanced Development & Safety Laboratories Limited on November 22, 2023.
Reported Earnings • Dec 01Second quarter 2024 earnings released: EPS: CA$0.004 (vs CA$0.007 in 2Q 2023)Second quarter 2024 results: EPS: CA$0.004 (down from CA$0.007 in 2Q 2023). Revenue: CA$2.07m (up 30% from 2Q 2023). Net income: CA$724.2k (down 33% from 2Q 2023). Profit margin: 35% (down from 68% in 2Q 2023).
Board Change • Sep 08High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Independent Chairman Greg Taylor is the most experienced director on the board, commencing their role in 2021. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 30First quarter 2024 earnings released: CA$0.001 loss per share (vs CA$0.031 profit in 1Q 2023)First quarter 2024 results: CA$0.001 loss per share (down from CA$0.031 profit in 1Q 2023). Revenue: CA$1.95m (up 29% from 1Q 2023). Net loss: CA$117.7k (down 103% from profit in 1Q 2023).
New Risk • Aug 01New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 1.2x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.2x net interest cover). Share price has been highly volatile over the past 3 months (17% average weekly change). High level of non-cash earnings (33% accrual ratio). Minor Risks Revenue is less than US$5m (CA$6.4m revenue, or US$4.8m). Market cap is less than US$100m (€9.46m market cap, or US$10.4m).
Reported Earnings • Aug 01Full year 2023 earnings released: EPS: CA$0.031 (vs CA$0.14 loss in FY 2022)Full year 2023 results: EPS: CA$0.031 (up from CA$0.14 loss in FY 2022). Revenue: CA$6.40m (down 12% from FY 2022). Net income: CA$5.08m (up CA$20.5m from FY 2022). Profit margin: 79% (up from net loss in FY 2022).
공고 • Jul 29Britannia Life Sciences Inc., Annual General Meeting, Sep 26, 2023Britannia Life Sciences Inc., Annual General Meeting, Sep 26, 2023.
New Risk • Jul 27New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €8.94m (US$9.84m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue has declined by 6.8% over the past year. Market cap is less than US$10m (€8.94m market cap, or US$9.84m). Minor Risk Revenue is less than US$5m (CA$6.5m revenue, or US$4.9m).
Buying Opportunity • Jul 26Now 29% undervalued after recent price dropOver the last 90 days, the stock is down 3.6%. The fair value is estimated to be €0.057, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 57% over the last 3 years. Earnings per share has declined by 4.3%.
Buying Opportunity • Apr 26Now 31% undervaluedOver the last 90 days, the stock is up 47%. The fair value is estimated to be €0.07, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 57% over the last 3 years. Earnings per share has declined by 4.3%.
Buying Opportunity • Mar 15Now 22% undervaluedOver the last 90 days, the stock is up 35%. The fair value is estimated to be €0.064, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 57% over the last 3 years. Earnings per share has declined by 4.3%.
Reported Earnings • Mar 02Third quarter 2023 earnings released: EPS: CA$0 (vs CA$0.083 loss in 3Q 2022)Third quarter 2023 results: EPS: CA$0 (improved from CA$0.083 loss in 3Q 2022). Revenue: CA$1.65m (flat on 3Q 2022). Net loss: CA$54.3k (loss narrowed 100% from 3Q 2022).
Reported Earnings • Nov 30Second quarter 2023 earnings releasedSecond quarter 2023 results: EPS: CA$0.007. Revenue: CA$1.59m (down 17% from 2Q 2022). Net income: CA$1.08m (up CA$1.88m from 2Q 2022). Profit margin: 68% (up from net loss in 2Q 2022).
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Greg Taylor was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Aug 31First quarter 2023 earnings released: EPS: CA$0.031 (vs CA$0.008 in 1Q 2022)First quarter 2023 results: EPS: CA$0.031 (up from CA$0.008 in 1Q 2022). Revenue: CA$1.51m (down 24% from 1Q 2022). Net income: CA$3.42m (up 449% from 1Q 2022).
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Greg Taylor was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Mar 10No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Director Greg Taylor was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
